Expression of high molecular weight cytokeratin-A novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma.

Jiajie G LuEmily T LoCleandrea WilliamsBrian MaAndy E SherrodGuang-Qian Xiao

Published in: The Prostate (2022)

PAC to be a novel type of innate ADT-resistant PAC. Overexpression of HMWCK in PAC can be potentially used as a surrogate biomarker for aggressive and innate hormone-refractory PACs. The genetic alterations imply potential therapeutic implications of PI3K/MAPK inhibitors in the treatment of these deadly diseases.

Keyphrases

immune response
poor prognosis
squamous cell carcinoma
machine learning
signaling pathway
oxidative stress
genome wide
deep learning
gene expression
benign prostatic hyperplasia
radical prostatectomy